Aequus Pharmaceuticals (AQS) AI Stock Analysis

• Market Cap: C$663.17K
• Dividend Yield: N/A
• Average Volume (3M): 65.80K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.40
• Revenue Growth: 129.21%
• EPS Growth: 26.79%
• Country: CA
• Employees: 12
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 132,634,430
• 10 Day Avg. Volume: 54,393
• 30 Day Avg. Volume: 65,797
• PEG Ratio: -0.02
• Price to Book (P/B): -3.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 21 Underperform
• Price Target: ―

Aequus Pharmaceuticals is experiencing severe financial difficulties with declining revenues, negative net income, and cash flow issues. These problems significantly impact the stock's attractiveness. The lack of technical analysis data and poor valuation metrics further contribute to a low overall stock score. The company may require drastic strategic measures to improve its financial health.

Aequus Pharmaceuticals Business Overview & Revenue Model

Company Description

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Aequus Pharmaceuticals generates revenue primarily through the sale of its developed and commercialized pharmaceutical products, particularly in the fields of ophthalmology and transplant therapy. Key revenue streams include direct sales of branded and partnered products, as well as potential royalty and milestone payments from collaboration agreements with other pharmaceutical companies. These partnerships often involve licensing agreements that allow Aequus to expand its market reach and leverage additional resources for product development and distribution. The company’s focus on improving existing therapies and targeting niche markets helps in maintaining a steady revenue flow while addressing critical healthcare needs.

Aequus Pharmaceuticals Financial Statement Overview

Summary

Aequus Pharmaceuticals is currently facing significant financial challenges, with declining revenues, persistent losses, and high leverage. The company's cash flow situation is strained, which could impact its operational capabilities and long-term viability. Strategic changes may be necessary to address these financial difficulties.

Income Statement

Aequus Pharmaceuticals has experienced declining revenues from 2021 to the TTM period with severe negative net income and EBIT margins. The company shows a negative revenue growth rate, indicating financial instability. The gross profit margin is also significantly low, reflecting challenges in maintaining profitability.

Balance Sheet

The balance sheet shows a worrying financial structure with negative stockholders' equity and a high debt-to-equity ratio. This indicates a leveraged position, which could pose risks in terms of financial sustainability. The equity ratio is negative, further highlighting financial distress.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating cash flow difficulties. However, the company managed some positive financing cash flow, showing a reliance on external financing. The free cash flow to net income ratio is negative, reflecting weak cash generation capabilities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
584.24K	254.90K	1.38M	2.71M	2.59M
	Gross Profit
199.97K	143.66K	1.15M	2.69M	2.59M
	EBIT
-2.13M	-2.82M	-2.50M	-1.35M	-521.57K
	EBITDA
-1.79M	-2.68M	-2.87M	-1.23M	-314.80K
	Net Income Common Stockholders
-2.18M	-2.96M	-3.21M	-1.81M	-1.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
50.24K	170.20K	294.67K	2.39M	1.72M
	Total Assets
800.28K	1.09M	1.69M	4.35M	3.13M
	Total Debt
6.61M	5.06M	782.92K	2.18M	2.32M
	Net Debt
6.56M	4.89M	533.10K	-211.31K	604.74K
	Total Liabilities
7.26M	5.38M	3.07M	2.56M	2.56M
	Stockholders Equity
-6.45M	-4.29M	-1.38M	1.79M	573.95K
Cash Flow		Free Cash Flow
-1.66M	-2.29M	-1.95M	-1.18M	-817.23K
	Operating Cash Flow
-1.66M	-2.29M	-1.95M	-1.17M	-804.91K
	Investing Cash Flow
44.85K	0.00	0.00	-507.96K	-12.32K
	Financing Cash Flow
1.49M	2.21M	-189.19K	2.40M	2.05M

Aequus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AQS, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.51 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AQS.

Aequus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	71 Outperform	C$96.78M	15.21	11.27%	―	-3.82%	-50.36%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
TGIF	44 Neutral	C$2.45M	―		―	-9.20%	93.62%
MVMD	35 Underperform	C$7.05M	―	-44.58%	―	-48.33%	47.56%
PHRX	29 Underperform	C$1.08M	―	-405.57%	―	―	-2291.11%
AQS	21 Underperform	C$663.17K	―	43.02%	―	129.21%	26.79%
VYYRF		$26.18M	―	-159.04%	―	―	―

Aequus Pharmaceuticals Corporate Events

Aequus Pharmaceuticals Reports Fiscal 2024 Results and Director Changes

Aequus Pharmaceuticals reported a decrease in operating loss for Fiscal 2024, attributed to increased revenue from the launch of ZIMED® PF and cost-cutting measures. Despite a net loss, the company saw a significant revenue increase and reduced general and administrative expenses, though sales and marketing costs rose due to advertising and consulting expenses. Additionally, Anne Stevens and Chris Clark resigned from the board of directors, marking a change in leadership.

Spark’s Take on TSE:AQS Stock

According to Spark, TipRanks’ AI Analyst, TSE:AQS is a Underperform.

Aequus Pharmaceuticals is currently struggling with financial instability, as reflected in its low financial performance score. Technical analysis indicates a bearish trend, which, along with a negative P/E ratio, contributes to its low valuation score. The lack of earnings call data and corporate events leaves the primary focus on the company’s financial challenges.

To see Spark’s full report on TSE:AQS stock, click here.